Patients TMS works. Why do fewer than 1% of eligible patients get it? A growing body of clinical evidence suggests that TMS can produce response rates of roughly 50-60% or higher.
Patients Why “rare disease” is a regulatory label, not a patient real... Regulators define a rare disease by how many people have it, and the answer depends on who is counting.
Patients From bedside to breakthroughs: Reimagining the human experie... Patients should be involved in the programme design process from the beginning, as co-creators with full influence over the outcome.
News Lilly partners with Hims & Hers on obesity drug sales Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies sold directly on the telehealth company's platform.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
